Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.
It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.
Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis.
It has a license agreement with Samil Pharma.
Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform.
Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 30, 24 | -0.98 Increased by +10.09% | -0.32 Decreased by -206.25% |
| Mar 29, 24 | -0.98 Decreased by -880.00% | -0.32 Decreased by -206.25% |
| Nov 22, 23 | -0.24 Decreased by -14.29% | -0.27 Increased by +11.11% |
| Aug 9, 23 | -0.95 Decreased by -533.33% | -0.34 Decreased by -179.41% |
| Jun 1, 23 | -1.09 Decreased by -263.33% | -1.50 Increased by +27.33% |
| Mar 29, 23 | -0.10 Increased by +66.67% | -0.14 Increased by +28.57% |
| Nov 16, 22 | -0.21 Increased by +32.26% | -0.16 Decreased by -31.25% |
| Aug 4, 22 | -0.15 Increased by +54.55% | -0.24 Increased by +37.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | N/A Decreased by N/A% | -2.02 M Decreased by -21.59% | - - |
| Dec 31, 23 | 0.00 Decreased by N/A% | -2.02 M Increased by +28.74% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -1.47 M Increased by +72.62% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -1.59 M Increased by +57.29% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -1.66 M Increased by +77.75% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -2.83 M Increased by +62.04% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -5.38 M Increased by +30.26% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -3.73 M Increased by +55.57% | Decreased by N/A% Decreased by N/A% |